Risk Factors, Therapy and Survival Outcomes of Small Cell and Large Cell Neuroendocrine Carcinoma of Urinary Bladder
Open Access
- 1 March 2014
- journal article
- Published by SAGE Publications in Rare Tumors
- Vol. 6 (1) , 10-14
Abstract
The risk factors, the optimal therapy and prognostic factors contributing to poor outcomes of neuroendocrine urinary bladder carcinoma are not fully elucidated because of its rarity. We reviewed the medical records of neuroendocrine bladder carcinoma patients treated at the University of Nebraska Medical Center between 1996 and 2011. Eighteen patients, 55% female with a median age of 77 years, had stage IV disease at diagnosis in 50% of cases. There was a high prevalence of smoking (78%), medical co-morbidities (94%), prior cancer history (22%) and family history of cancer (61%). Treatment modalities included surgery (72%), platinum-based chemotherapy (50%) and/or radiation (22%). Median overall survival was 18.5 months (95% confidence interval, 7-36 months). Patients with Stage II and III cancer who underwent radical surgery with or without neoadjuvant chemotherapy had a median survival of 37 months. In addition to smoking, for the first time, our study indicates that the personal or family history of cancer may increase risk to neuroendocrine bladder cancer. Advanced age and stage at diagnosis, and the presence of multiple co-morbidities contribute to poor overall survival. Patients with early-stage disease are likely to benefit from a combination of radical surgery and platinum-based neoadjuvant chemotherapy.Keywords
This publication has 28 references indexed in Scilit:
- A Case of the Large Cell Neuroendocrine Carcinoma of the Urinary BladderCase Reports in Medicine, 2013
- Large cell neuroendocrine carcinoma (LCNEC) of the urinary bladder: a case reportDiagnostic Pathology, 2013
- Significant activity of single agent vinorelbine against small-cell cancer of the bladder as second line chemotherapy: A case series and review of the literatureUrologic Oncology: Seminars and Original Investigations, 2012
- A Surveillance, Epidemiology, and End Results analysis of small cell carcinoma of the bladderCancer, 2011
- A rare bladder cancer - small cell carcinoma: review and updateOrphanet Journal of Rare Diseases, 2011
- Symptomatic brain metastases from small-cell carcinoma of the urinary bladder: The Netherlands Cancer Institute experience and literature reviewAnnals of Oncology, 2010
- Outcome of recurrent and metastatic small cell carcinoma of the bladderBMC Urology, 2009
- Long-term survival after sequential chemoradiation for limited disease small cell carcinoma of the bladderWorld Journal of Urology, 2008
- Familial aggregation of urothelial cell carcinomaInternational Journal of Cancer, 2001
- Bladder and Kidney Cancer Following Cyclophosphamide Therapy for Non-Hodgkin's LymphomaJNCI: Journal of the National Cancer Institute, 1995